HLN

MKT CAP:$43B

Haleon plc

Market Cap

$43B

Healthcare·Drug Manufacturers - Specialty & Generic·🇬🇧 United Kingdom·NYSE

Healthcare·Drug·🇬🇧·NYSE

Stock Price

$9.60-$0.40 (-4.00%)

Apr 24, 2026

Company Details

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral ...

CEO

Brian James McNamara

IPO Date

Jul 25, 2022

Website

www.haleon.com

Key Metrics TTM

Revenue

$26.0B

+13.7% YoY

Net Income

$3.7B

EPS (Diluted)

$0.83

Free Cash Flow

$3.1B

Revenue / Share

$5.80

Gross Margin

63.8%

Operating Margin

21.3%

Net Margin

14.4%

FCF Margin

11.9%

P/S

1.6x

P/E

11.4x

Earnings Reports

Q1 2026

Apr 29, 2026

PENDING

FY 2025

Mar 13, 2026

$14.5B-4.0%EPS $0.49

Q4 2025

Mar 13, 2026

$7.4B-0.4%EPS $0.26

Q2 2025

Jun 30, 2025

$7.4B-3.8%EPS $0.24

Q1 2025

Mar 31, 2025

$3.7B-6.1%EPS $0.12

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 23	$7.7B	$4.8B	$1.5B
Q4 23	$7.5B	$4.3B	$1.2B
Q1 24	$3.9B	$2.5B	$883M
Q2 24	$7.7B	$4.9B	$1.6B
Q3 24	$3.7B	$2.4B	$951M
Q4 24	$7.5B	$4.6B	$1.4B
Q1 25	$3.7B	$2.4B	$811M
Q2 25	$7.4B	$4.8B	$1.6B
Q4 25	$7.4B	$4.8B	$1.7B

Valuation

Quarter	P/S	P/E
Q2 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	1.4x	12.9x
Q3 24	2.1x	18.0x
Q4 24	1.9x	13.8x
Q1 25	2.1x	15.1x
Q2 25	2.1x	14.7x
Q4 25	1.8x	12.2x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 23	$0	$0
Q4 23	$0	$0
Q2 24	$0	$0
Q4 24	$0	$0
Q2 25	$1.5B	$1.4B
Q4 25	$2.0B	$1.7B

Capital Expenditures

Quarter	CapEx
Q2 23	$0
Q4 23	$0
Q2 24	$0
Q4 24	$0
Q2 25	$129M
Q4 25	$307M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 24	-51.6%	-54.9%
Q4 24	-0.4%	-4.8%
Q1 25	-6.1%	-5.5%
Q2 25	-3.8%	-5.9%
Q4 25	+98.4%	+105.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 23	$49M	0.6%
Q4 23	$119M	1.6%
Q2 24	$66M	0.9%
Q4 24	$138M	1.8%
Q2 25	$57M	0.8%
Q4 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q2 23	$191M	$3.0B	—	—
Q4 23	$228M	—	$2.7B	—
Q1 24	$96M	$1.5B	—	—
Q2 24	$194M	$3.0B	—	—
Q3 24	$102M	$1.5B	—	—
Q4 24	$208M	$3.0B	—	—
Q1 25	$103M	—	—	$1.5B
Q2 25	$206M	—	—	$2.9B
Q4 25	$218M	—	—	$2.9B

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 21	$0	$901M	$901M
Q4 21	$558M	$0	$558M
Q2 22	$1.8B	$0	$1.8B
Q4 22	$817M	$105M	$922M
Q2 23	$661M	$0	$661M
Q4 23	$1.4B	$0	$1.4B
Q2 24	$716M	$0	$716M
Q4 24	$3.0B	$74M	$3.0B
Q2 25	$911M	$0	$911M
Q4 25	$1.8B	$0	$1.8B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 23	4.63B	—	—
Q4 23	4.62B	-0.2%	—
Q1 24	4.60B	-0.6%	—
Q2 24	4.61B	+0.2%	—
Q3 24	4.56B	-1.0%	-1.5%
Q4 24	4.61B	+1.0%	-0.3%
Q1 25	4.53B	-1.7%	-1.4%
Q2 25	4.53B	0.0%	-1.6%
Q4 25	4.48B	-1.1%	-1.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 23	$314.2K	25K
Q4 23	$295.2K	25K
Q1 24	$154.9K	25K
Q2 24	$302.1K	25K
Q3 24	$147.5K	25K
Q4 24	$721.8K	10K
Q1 25	$357.1K	10K
Q2 25	$714.1K	10K
Q4 25	$718.8K	10K

Revenue / Employee